Dr. Harry Angelman was the first to describe the Angelman syndrome (AS) in 1965. AS is a kind of neurological development-impacting genetic disease.[1] The prevalence of AS has been estimated to be approximately 1 in 15,000 individuals.[2] Furthermore, AS has been verified to be a maternally inherited disorder caused by the dysfunction of the ubiquitin-protein ligase E3A (UBE3A) gene that encodes ubiquitin-protein ligase E3A. To date, 4 molecular variants have been identified to be involved in AS pathogenesis: the maternal heritage deletion of the chromosome 15q11.2-q13 critical region, paternal uniparental disomy 15 (UPD), imprinting center defect, and the mutation maternal inherited by the UBE3A gene.[